Unusual Options Activity Sparks Interest in Ocugen’s Gene Therapy Prospects

International Partnership Expands Market Reach

A surge in bullish options trading has drawn significant attention to biotech firm Ocugen, with market participants taking substantial positions anticipating further share price appreciation. This unusual trading pattern raises questions about whether investors have identified genuine potential or are engaging in speculative bets on the company’s future.

Ocugen recently secured a licensing agreement with Kwangdong Pharmaceutical for exclusive Korean rights to its flagship gene therapy candidate, OCU400. The financial terms of this arrangement include:
– Upfront payments and development milestones totaling $7.5 million
– Commercial milestone payments of $1.5 million for every $15 million in Korean sales
– Royalty payments amounting to 25% of net sales